Amphastar Pharma

Amphastar Pharmaceuticals, Inc. engages in developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, and insulin active pharmaceutical ingredient. It operates through Finished Pharmaceutical Products and Active Pharmaceutical Ingredients Products segments. The Finished Pharmaceutical Products segment manufactures, markets, and distributes Primatene Mist, enoxaparin, naloxone, phytonadione, lidocaine, and other critical and non-critical care drugs. The Active Pharmaceutical Ingredients Products segment offers RHI API and porcine insulin API for external customers and internal product development. The company was founded by Zi-Ping Luo and Yong Feng Zhang on February 29, 1996 and is headquartered in Rancho Cucamonga, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amphastar Pharma excels in Q4 with strong revenue growth and product success

Amphastar Pharma's Q4 2022 performance reflects strong revenue growth, profitability, and product success, positioning the company well for future growth.
The company's focus on high-margin products, FDA approvals, and strategic investments in marketing and R&D underscore its commitment to innovation and market competitiveness.
While facing challenges in sustaining growth and managing costs, Amphastar Pharma has opportunities for expansion through product development, market penetration, and strategic initiatives.

Amphastar Pharma excels in Q1 2023, eyes growth opportunities

Amphastar Pharma's Q1 2023 showcased robust financial performance, driven by revenue growth and strategic product initiatives.
While facing challenges in market dynamics and margin management, the company is well-positioned to capitalize on growth opportunities.
With a focus on innovation, market expansion, and financial strength, Amphastar Pharma demonstrates resilience and potential for sustained success.

Amphastar Pharma excels in Q2 with revenue growth and innovation

Amphastar Pharma's Q2 2023 performance reflects strong revenue growth, improved profitability, and operational efficiency, underpinned by robust sales across key products.
While facing challenges such as FDA approval delays and pipeline setbacks, the company's strategic focus on proprietary products and innovation presents opportunities for sustained growth.
By capitalizing on market demand, enhancing margins, and advancing its product pipeline, Amphastar is poised to navigate challenges and capitalize on opportunities for long-term success.

Amphastar Pharma excels in Q3 with robust revenue growth

Amphastar Pharma delivered impressive financial results in Q3 2023, marked by significant revenue growth and profitability improvements.
While facing challenges in sustaining rapid sales growth and managing debt obligations, the company's strategic focus on product expansion and market presence presents growth opportunities.
Overall, Amphastar Pharma's strong performance, diverse product portfolio, and financial stability position it well for future growth and value creation for stakeholders.

Amphastar Pharma excels in Q4 2023, eyes growth opportunities

Amphastar Pharma's Q4 2023 performance reflects robust growth in revenues, profit, and net income, driven by strategic focus and product demand.
While facing challenges like lower gross margins and capacity expansions, the company is poised for growth through innovation and market opportunities.
Opportunities lie in R&D advancements, product launches, and financial strength, positioning Amphastar Pharma for continued success and expansion.

Amphastar Pharma excels in Q1 2024, eyes growth through innovation

Amphastar Pharma's Q1 2024 showcases strong financial performance and strategic focus on product innovation and market expansion. While facing challenges in pricing and regulatory landscape, the company is poised for growth through new product launches and market penetration strategies.

Amphastar Pharma reports revenue growth amidst margin challenges and regulatory hurdles

Amphastar Pharma's Q3 performance showed revenue growth driven by key products.
While facing challenges in net income and margins, the company aims for sustainable growth.
Opportunities lie in product launches, market expansion, and regulatory progress.
Overall, Amphastar Pharma navigates financial challenges with strategic initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Catalyst Pharmaceuticals

Enliven Therapeutics Inc

Horizon Pharma

Vertex Pharmaceuticals

The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.

The Cream Of The Crop: 5 Biotech Stocks That Outrank 91% Of All Stocks

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

Amphastar Pharmaceuticals (AMPH)'s Technical Outlook is Bright After Key Golden Cross

Deere & Company

Expectations for the next FOMC meeting have seen odds of a 50bps rate hike go from extremely unlikely to highly likely

2 Stocks to Buy Now After Powell Flips the Narrative

RANCHO CUCAMONGA, CA / ACCESSWIRE / March 8, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") announced that the U.S. Food and Drug Administration ("FDA") has granted approval of its New Drug Application ("NDA") for naloxone hydrochloride nasal spray 4mg, which is delivered utilizing the Company's proprietary nasal delivery device. Naloxone hydrochloride nasal spray 4mg is indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression for adult and pediatric patients.

Amphastar Pharmaceuticals Receives FDA Approval for Naloxone Hydrochloride Nasal Spray 4mg

The company reported a record revenue year and increased EPS.

Why Shares of Amphastar Pharmaceuticals Rose Today

Amphastar (AMPH) delivered earnings and revenue surprises of 92.11% and 6.80%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Amphastar Pharmaceuticals (AMPH) Q4 Earnings and Revenues Beat Estimates

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH ) Q4 2022 Earnings Conference Call February 28, 2023 5:00 PM ET Company Participants Bill Peters - Chief Financial Officer, Treasurer, Executive Vice President of Finance, and President of IMS Ltd., and Director Dan Dischner - VP of Human Resources and Corporate Communication Tony Marrs - Sr. VP of Regulatory Affairs and Sr. VP of Clinical Operations Conference Call Participants Timothy Chiang - Capital One David Amsellem - Piper Sandler Operator Greetings, and welcome to the Amphastar Pharmaceuticals Fourth Quarter Earnings Call.

Amphastar Pharmaceuticals, Inc. (AMPH) Q4 2022 Earnings Call Transcript

Reports Net Revenues of $135.0 Million for the Three Months Ended December 31, 2022 RANCHO CUCAMONGA, CA / ACCESSWIRE / February 28, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months and full-year ended December 31, 2022. Fourth Quarter Highlights Net revenues of $135.0 million for the fourth quarter GAAP net income of $33.9 million, or $0.66 per share, for the fourth quarter Adjusted non-GAAP net income of $37.6 million, or $0.73 per share, for the fourth quarter Full-Year Highlights Net revenues of $499.0 million for the fiscal year GAAP net income of $91.4 million, or $1.74 per share, for the fiscal year Adjusted non-GAAP net income of $103.2 million, or $1.97 per share, for the fiscal year Dr. Jack Zhang, Amphastar's President and Chief Executive Officer, commented: "We are pleased to report our strongest quarter yet, driven by sales of epinephrine, Primatene MIST®, glucagon, and other finished pharmaceutical products.

Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2022

RANCHO CUCAMONGA, CA / ACCESSWIRE / February 22, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its fourth quarter of 2022 ended December 31, 2022, after the market closes on Tuesday, February 28, 2023, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.

Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 28, 2023

Amphastar stock has generated high rates of post-tax earnings growth with small increments of additional capital investment since FY20. The incremental returns on capital are above historical returns on capital, illustrating the profitability of recent product launches over the legacy portfolio.

Amphastar: Generating High Incremental Growth From Tidy Earnings Reinvestment

Dr. Reddy's Labs

Sol-Gel Technologies

The impact of inflationary headwinds and pricing pressure on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and SLGL.

3 Generic Drug Stocks to Watch Amid Inflation Pressures

RANCHO CUCAMONGA, CA / ACCESSWIRE / November 22, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Tony Marrs, Sr. Vice President Regulatory Affairs and Clinical Operations, will participate in an Analyst-Moderated fireside chat at the Piper Sandler 34th Annual Healthcare Conference on November 30th, 2022 at 11:00 am Eastern Time. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com.

Amphastar Pharmaceuticals to Present at the Piper Sandler 34th Annual Healthcare Conference

Quarter-over-Quarter growth in revenue has persisted due to the consistent launch of new product pipelines. The overall financial position is substantially strong, which offers significant flexibility for the company.

Amphastar: Growth Remains Intact

RANCHO CUCAMONGA, CA / ACCESSWIRE / November 10, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Jacob Liawatidewi, Executive V.P. of Corporate Administration Center, will participate in an Analyst-Moderated fireside chat at the 2022 Jefferies London Healthcare Conference on November 16th , 2022 at 3:50 pm Greenwich Mean Time.

Amphastar Pharmaceuticals to Present at the 2022 Jefferies London Healthcare Conference

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH ) Q3 2022 Results Conference Call November 7, 2022 5:00 PM ET Company Participants Dan Dischner - Vice President, Corporate Communications Bill Peters - Chief Executive Officer Dan Dischner - Vice President of Corporate Communications Tony Marrs - Senior Vice President of Regulatory Affairs and Clinical Operations Conference Call Participants David Amsellem - Piper Sandler Serge Belanger - Needham & Company Elliot Wilbur - Raymond James Operator Greetings, and welcome to the Amphastar Pharmaceuticals, Inc. Third Quarter Earnings Call. At this time, all participants are in a listen-only mode.

Amphastar Pharmaceuticals, Inc. (AMPH) Q3 2022 Earnings Call Transcript

Amphastar (AMPH) delivered earnings and revenue surprises of 0% and 4.81%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Amphastar Pharmaceuticals (AMPH) Q3 Earnings Meet Estimates

Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Amphastar Pharmaceuticals (AMPH) Q3 Earnings Expected to Decline

RANCHO CUCAMONGA, CA / ACCESSWIRE / October 28, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2022 ended September 30, 2022, after the market closes on Monday, November 7, 2022, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.

Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 7, 2022

Amphastar's profitability and cash flow have been increasing consistently, and with management's efforts, profitability will increase significantly. Having a solid financial position and consistent growth will eventually lead to a more sustainable business model, and in such cases, valuation will not remain at this level.

Amphastar: A Pharmaceutical Growth Stock

Black Stone Minerals LP

Commercial Metals

Campbell Soup

Dollar General

Global Partners

NAPCO Security Technologies

Back in August, I made the argument why now's the right time to buy safe stocks. Just over a month later, this continues to be the case.

7 Safe Stocks to Rely on When the Market Swerves

RANCHO CUCAMONGA, CA / ACCESSWIRE / September 2, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jacob Liawatidewi, Executive V.P. of Corporate Administration Center and Sales and Marketing and Tony Marrs Sr. Vice President of Regulatory Affairs and Clinical Operations, will participate in an Analyst-Moderated fireside chat at the Wells Fargo 2022 Healthcare Conference on September 7th, 2022 at 1:20 pm Eastern Standard Time.

Amphastar Pharmaceuticals to Present at the Wells Fargo 2022 Healthcare Conference

RANCHO CUCAMONGA, CA / ACCESSWIRE / August 16, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's New Drug Application ("NDA") for Epinephrine injection USP, 1 mg/10mL (0.1 mg/mL) Single Dose Pre-Filled Syringe. Epinephrine injection is indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock.

Amphastar Pharmaceuticals Receives FDA Approval for Epinephrine Pre-Filled Syringes

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH ) Q2 2022 Results Earnings Conference Call August 8, 2022 5:00 PM ET Company Participants Dan Dischner - Vice President, Corporate Communications Bill Peters - Chief Financial Officer, Treasurer, Executive Vice President of Finance, and President of International Medication Systems, Ltd. Tony Marrs - Senior Vice President, Regulatory Affairs Conference Call Participants Tim Chiang - Capital One Elliot Wilbur - Raymond James Serge Belanger - Needham & Company, LLC David Amsellem - Piper Jaffray Operator Greetings and welcome to the Amphastar Pharmaceuticals Second Quarter Earnings Call.

Amphastar Pharmaceuticals, Inc. (AMPH) Management on Q2 2022 Results - Earnings Call Transcript

Syndax Pharmaceuticals

Amphastar and Syndax, two top-rated biotech stocks, topped second-quarter estimates on Tuesday. But shares stayed flat.

Amphastar, Syndax Top Second-Quarter Estimates, But Runaway Biotechs At A Standstill

Reports Net Revenues of $123.5 Million for the Three Months Ended June 30, 2022 RANCHO CUCAMONGA, CA / ACCESSWIRE / August 8, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended June 30, 2022. Second Quarter Highlights Net revenues of $123.5 million for the second quarter GAAP net income of $17.3 million, or $0.33 per share, for the second quarter Adjusted non-GAAP net income of $20.7 million, or $0.39 per share, for the second quarter Dr. Jack Zhang, Amphastar's President and Chief Executive Officer, commented: "We've maintained momentum through the first half of 2022.

News for Amphastar Pharma Stock (AMPH)